Related Experiment Videos
Transurethral resection for muscle-invasive bladder cancer
1Department of Urology, Municipal Péterffy Sándor Street Hospital, Budapest, Hungary.
International Urology and Nephrology
|January 1, 1993
Summary
Radical transurethral resection for muscle-invasive bladder cancer (T2-T3a) showed 20% morbidity and 1% mortality. This bladder-sparing approach may offer an alternative to cystectomy in select patients.
Area of Science:
- Urology
- Oncology
- Surgical Oncology
Background:
- Muscle-invasive bladder cancer (MIBC) necessitates aggressive treatment.
- Radical cystectomy is the standard treatment for MIBC, but carries significant morbidity.
- Transurethral resection (TUR) offers a less invasive option, but its role in MIBC requires further investigation.
Purpose of the Study:
- To evaluate the perioperative morbidity, mortality, and long-term outcomes of radical transurethral resection (TUR) for muscle-invasive bladder cancer (MIBC).
- To assess the efficacy of TUR as a bladder-sparing alternative to cystectomy in select MIBC patients.
Main Methods:
- A retrospective analysis of 103 patients with T2-T3a MIBC who underwent radical TUR.
- Data collected included perioperative morbidity, mortality, tumor recurrence, progression, and survival rates.
- Adjuvant treatment protocols were also considered in the analysis.
Main Results:
- Perioperative morbidity was 20% and mortality was 1% in the radical TUR group.
- Three- and five-year survival rates were 54% and 36%, respectively.
- Within 5 years, 46% experienced tumor relapse and 33% showed progression. Tumor-related death occurred in 29% of patients.
Conclusions:
- Radical transurethral resection for T2-T3a MIBC demonstrates acceptable perioperative outcomes.
- While recurrence and progression rates are notable, radical TUR combined with adjuvant therapy may be a viable bladder-sparing alternative to cystectomy for carefully selected MIBC patients.